Search results for "Marker"

showing 10 items of 3799 documents

Overexpression of ALDH1 and EMT marker profile are linked with unfavorable outcome in head and neck cancer

2020

Background The aim of this research was to assess the expression of aldehyde dehydrogenase 1 (ALDH1) and epithelial-mesenchymal transition (EMT) markers in head and neck squamous cell carcinoma (HNSCC), and to correlate them with the clinical and histopathological parameters of a patient cohort with follow-up over an 8-year period. Material and Methods For this, seventeen HNSCC and non-neoplastic adjacent epithelium (AE) samples were subjected to laser microdissection and real-time PCR to evaluate the mRNA expression of ALDH1, E-cadherin (E-CAD), N-cadherin (N-CAD), and vimentin (VIM). Also, immunohistochemistry was performed for ALDH1, E-CAD, N-CAD, and VIM in the tumor center (TC), invasi…

Oncologymedicine.medical_specialtyEpithelial-Mesenchymal Transitionmedicine.medical_treatmentVimentinAldehyde Dehydrogenase 1 FamilyMetastasis03 medical and health sciences0302 clinical medicineInternal medicineBiomarkers TumormedicineHumansEpithelial–mesenchymal transitionGeneral DentistryLaser capture microdissectionOral Medicine and PathologybiologySquamous Cell Carcinoma of Head and Neckbusiness.industryResearchHead and neck cancer030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Head and neck squamous-cell carcinomaRadiation therapyOtorhinolaryngologyHead and Neck NeoplasmsUNESCO::CIENCIAS MÉDICASbiology.proteinImmunohistochemistrySurgeryNeoplasm Recurrence Localbusiness
researchProduct

Immune cell score, PD-L1 expression and prognosis in esophageal cancer.

2021

Esophageal cancer (EC) is the ninth most common cancer worldwide and the sixth leading cause of cancer death [1]. Despite improvements in the treatment of EC, the general outcome remains poor [2–4]...

Oncologymedicine.medical_specialtyEsophageal NeoplasmsCellMEDLINEB7-H1 Antigen030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingCancer deathbusiness.industryCancerHematologyGeneral MedicineEsophageal cancermedicine.diseasePrognosismedicine.anatomical_structureOncology030220 oncology & carcinogenesisPd l1 expressionbusinessActa oncologica (Stockholm, Sweden)
researchProduct

The Vegf Pathway in Patients with Pancreatic Neuroendocrine Tumors: Efficacy of Everolimus by Baseline Marker Level, and Prognostic and Predictive Ef…

2012

ABSTRACT Background RADIANT-3 was a phase III study investigating the effect of the mammalian target of rapamycin inhibitor everolimus on progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumors (pNET; Yao et al, NEJM, 2011). Everolimus significantly improved PFS compared with placebo (11 vs 4.6 months, P  Methods Baseline plasma levels of VEGF-A, PlGF, sVEGFR1, and sVEGFR2 were determined by ELISA using multiplexed MSD platform. The optimal cutoffs for these markers were explored using the “survival tree analysis” method. Interaction of treatment and baseline marker status ( Results PFS was significantly improved to a similar extent in patients receiving e…

Oncologymedicine.medical_specialtyEverolimusbusiness.industryHematologyPlasma levelsNeuroendocrine tumorsmedicine.diseasePlaceboOncologyMarker statusInternal medicinemedicineIn patientTreatment effectbusinessSurvival treemedicine.drugAnnals of Oncology
researchProduct

Snps in Angiogenic Factors As Predictive Markers for Outcome in Patients (P) with Advanced Non-Squamous Nsclc (NS-NSCLC) Treated with Carboplatin, Pa…

2015

Oncologymedicine.medical_specialtyGroup trialPredictive markerBevacizumabbusiness.industryHematologymedicine.diseaseCarboplatin/paclitaxelCarboplatinchemistry.chemical_compoundOncologychemistryPaclitaxelNon squamousInternal medicinemedicineLung cancerbusinessmedicine.drugAnnals of Oncology
researchProduct

The Role of HSP70 in the Diagnosis of HCC

2015

ABSTRACT: Hepatocellular carcinoma (HCC) is a common tumor with a fatal clinical outcome if not diagnosed at an early stage. To date there is still a lack of reliable tumor biomarkers to detect asymptomatic precursor lesions in early HCC. Conventional pathological analysis also often fails to achieve sufficient sensitivity and specificity to diagnose early HCC. Genetic, proteomic, immunohistochemical, and liquid biopsy analysis indicate a role for members of the heat-shock protein 70 (HSP70) family as potential tumor-specific markers for HCC. The aim of this review is to revisit the existing literature and to specifically explore HSP70 as a molecular tumor biomarker for the detection of HCC…

Oncologymedicine.medical_specialtyKEY WORDS: Diagnosis of HCC Hsp70 liquid biopsy tumor biomarkerSettore MED/09 - Medicina Internabusiness.industryInternal medicineGeneticsmedicineMolecular MedicineLiquid biopsybusinessBiochemistryBiotechnology
researchProduct

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

2021

ABSTRACT Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in non-squamous NSCLC. We conducted a retrospective study of patients receiving ICI for advanced non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were generated on tumor biopsy taken before ICI. The primary end point was progression-free survival under ICI. Secondary end point was overall survival from ICI initiation. In the cohort, we studied 231 patients. Clinico-pathological characteristics included KRAS mutant status (n = 88), TTF1-…

Oncologymedicine.medical_specialtyLIPI scoreLung Neoplasmsmedicine.medical_treatmentImmunologyThyroid Nuclear Factor 1Adenocarcinoma of Lungmedicine.disease_causeTTF1Internal medicinePD-L1Carcinoma Non-Small-Cell LungmedicineClinical endpointKRASImmunology and AllergyHumansLung cancerImmune Checkpoint InhibitorsRC254-282Retrospective StudiesOriginal Researchbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensprognostic factorsRetrospective cohort studyImmunotherapyRC581-607medicine.diseasePrognosisOncologyCohortbiology.proteinAdenocarcinomaKRASimmunotherapyImmunologic diseases. AllergybusinessAdenocarcinoma lung cancerBiomarkersResearch ArticleOncoimmunology
researchProduct

E-Cadherin gene expression in oral cancer: Clinical and prospective data

2019

Background Low protein expression of E-cadherin in oral squamous cell carcinoma (OSCC) has been associated with clinical and histopathological traits such as metastases, recurrence, low survival and poor tumor differentiation, and it is considered a high-risk marker of malignancy. However, it is still unknown whether low expression of E-cadherin is also present at the mRNA level in OSCC cases. Objective: The aim of this study was to compare E-cadherin mRNA expression in OSCC patients and controls and to correlate the expression with clinical and prospective characteristics. Material and Methods Forty patients and 40 controls were enrolled. E-cadherin mRNA expression was evaluated by quantit…

Oncologymedicine.medical_specialtyLow proteinMalignancyMetastasis03 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineCarcinomaHumansProspective StudiesProspective cohort studyGeneral DentistryMouth neoplasmOral Medicine and PathologyE-Cadherinbusiness.industryResearchOral cancerCancer030206 dentistryCadherinsPrognosis:CIENCIAS MÉDICAS [UNESCO]medicine.diseasestomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellMouth NeoplasmsSurgeryGene expressionNeoplasm Recurrence LocalbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and L…

2020

Background: Lung neuroendocrine carcinoma (NEC) is characterized by aggressive clinical behavior and lack of treatment advances. We evaluate the prognostic and the predictive roles of systemic inflammatory biomarkers in patient circulating blood: neutrophil–lymphocyte ratio (NLR), lactate dehydrogenase (LDH), advanced lung cancer inflammation index (ALI), and the Lung Immune Prognostic Index (LIPI) score. Methods: A total of 120 patients with small-cell lung cancer (SCLC) ( n = 110) and large cell neuroendocrine carcinoma (LCNEC) ( n = 10) were enrolled. Overall survival (OS) was evaluated by Kaplan–Meier estimator and univariate and multivariate Cox proportional hazard analyses were perfor…

Oncologymedicine.medical_specialtyLungBlood based biomarkersbusiness.industrySettore MED/06 - Oncologia Medicasmall-cell lung cancer (SCLC)systemic inflammatory responselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInflammatory biomarkerslcsh:RC254-282Neuroendocrine Carcinomasmedicine.anatomical_structureOncologyInternal medicinemedicinePrognostic biomarkerNeuroendocrine carcinomaOriginal Articlebusinesspredictive biomarkerprognostic biomarkerneuroendocrine tumorPredictive biomarkerblood-based biomarker
researchProduct

Non-Hodgkin B-cell lymphoma involving the palate.

2018

Oncologymedicine.medical_specialtyLymphoma B-CellPalatal Neoplasmsbusiness.industryTreatment outcomeRemission InductionPalatal NeoplasmsChemoradiotherapymedicine.diseaseRemission inductionTreatment OutcomeOncologyInternal medicinemedicineBiomarkers TumorHumansFemalePalatal NeoplasmB-cell lymphomabusinessChemoradiotherapyHumanAgedThe Lancet. Oncology
researchProduct

Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review

2019

Background: The goal of this paper was to identify available biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw (BRONJ). Material and Methods: Case-control studies comparing the different concentrations of a series of molecules detected in serum and urine as matrices of BRONJ affected patients vs. non-affected were included. PRISMA guidelines for systematic reviews were used for the present paper. Two reviewers independently screened electronic databases (Medline, Web of science, and The Cochrane Library) and performed hand searches. Risk of bias assessment of selected studies was performed by the Newcastle-Ottawa Scale. This study is registered as PROSPERO CR…

Oncologymedicine.medical_specialtyMEDLINEReviewCochrane LibraryRisk Assessment03 medical and health sciences0302 clinical medicineBiphosphonatePredictive Value of TestsInternal medicinemedicineHumansGeneral DentistryOral Medicine and PathologyBisphosphonate-associated osteonecrosis of the jawbusiness.industryCase-control study030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngologyCase-Control Studies030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgerybusinessRisk assessmentOsteonecrosis of the jawBiomarkers
researchProduct